|Bid||1.5800 x 900|
|Ask||1.5900 x 800|
|Day's Range||1.5500 - 1.6000|
|52 Week Range||1.1300 - 2.4800|
|Beta (3Y Monthly)||0.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.00|
NewLink Genetics Corporation (NLNK) announced today that Friday, October 18th, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a conditional marketing authorization for investigational V920 Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP), as confirmed by our partner, Merck & Co., Inc. (MRK). This Committee recommendation will now be reviewed by the European Commission (EC) which, if it chooses to affirm the CHMP’s recommendation, will grant a centralized marketing authorization of the vaccine (brand name ERVEBO®) under a unified label valid in 31 European countries. Should this vaccine be approved by the FDA, a monetizable Priority Review Voucher (PRV) would be issued, in which NewLink Genetics owns a substantial financial interest.
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the NYSE/Nasdaq-listed biotech stocks hit 52-week highs on Oct. 1. Down In The Dumps (Biotech stocks hitting 52-week ...
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 30.) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ...
NewLink Genetics Corporation (NLNK) and Lumos Pharma, Inc., a private clinical stage biopharmaceutical company focused on development and commercialization of therapeutics for rare diseases, today announced that the companies have entered into a definitive merger agreement. Under the terms of the agreement, NewLink will issue Lumos Pharma stockholders NewLink common stock in exchange for their shares in Lumos such that Lumos Pharma stockholders will own approximately 50% of NewLink.
Potential approval of the vaccine will trigger issuance of a priority review voucher owned by Merck and in which NewLink has a substantial economic interest. The priority review voucher program was created by the U.S. Congress in 2007, and under the program, on approval of a treatment for a neglected or rare pediatric disease, the developer will be issued a voucher for priority review for a different drug as a means of incentivizing development of treatments for neglected and rare diseases. "We are pleased with this morning's announcement from our partner, Merck.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 17.) 10X Genomics Inc (NASDAQ: TXG ) (listed ...
NewLink Genetics Corporation (NLNK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Merck’s Biologics License Application (BLA) and granted priority review for the investigational Ebola vaccine (V920), for the prevention of disease caused by the Ebola Zaire virus. Merck’s rolling submission was made pursuant to the FDA’s Breakthrough Therapy Designation for V920, a designation awarded to our partner, Merck, in July 2016. As NewLink has previously stated, the FDA’s approval of this Ebola vaccine would trigger the issuance of a priority review voucher owned by Merck and in which NewLink Genetics has a substantial economic interest.
Investors need to pay close attention to NewLink Genetics (NLNK) stock based on the movements in the options market lately.
Every investor in NewLink Genetics Corporation (NASDAQ:NLNK) should be aware of the most powerful shareholder groups...
AMES, Iowa, July 30, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) (“NewLink Genetics” or the “Company”) today announced financial results for the second quarter ended.
Anyone researching NewLink Genetics Corporation (NASDAQ:NLNK) might want to consider the historical volatility of the...
Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
NLG802, a prodrug of indoximod, produced significantly higher pharmacokinetic (PK) exposure in patients compared to molar equivalent of indoximod while maintaining encouraging.
On a per-share basis, the Ames, Iowa-based company said it had a loss of 27 cents. The biopharmaceutical company posted revenue of $106,000 in the period. In the final minutes of trading on Wednesday, ...
AMES, Iowa, May 08, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced financial results for the first quarter ended March 31, 2019 and provided an update on.
AMES, Iowa, May 06, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor and medical conferences:.
NewLink Genetics Corporation's (NASDAQ:NLNK) released its most recent earnings update in December 2018, which indicated that losses became smaller relative to the prior year's level - great news for...
NewLink Genetics Corporation (NLNK) today announced it will host its first quarter 2019 conference call and webcast at 4:30 PM ET on Wednesday, May 8, 2019, to discuss its first quarter financial results and provide an update of its clinical development activities. Investors and the general public are invited to listen to a live audio webcast of the conference call, which can be accessed five minutes prior to the start of the call by dialing (855) 469-0612 (U.S.) or (484) 756-4268 (international). The conference call will be webcast live and a link can be accessed through the NewLink Genetics website at https://edge.media-server.com/m6/p/df4rgjiz.
AMES, Iowa, April 02, 2019 -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced results from a Phase 2 study of NLG207, a nanoparticle formulation of the topoisomerase.
The biotech space is witnessing a rally so far in 2019. Here we discuss four stocks that are likely to witness a continuation of the uptrend going ahead.